RPRX · Royalty Pharma plc · Webcasts, Transcripts & Audio
$69.08
-0.23 (-0.33%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$39.76B
Shares
573.61M
Volume · Nov 16
885.81K
Avg daily vol (3M)
3.14M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Royalty Pharma plc Webcasts
Earnings calls, investor updates, investor days and conferences for Royalty Pharma plc (RPRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Royalty Pharma plc (RPRX) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Confident tone
China licensing opportunity
New royalty acquisitions
Portfolio and receipt growth
Revenue
$690.10M
▲ 13.3% YoY Diluted EPS
$0.32
▼ 51.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-23
Royalty Pharma plc (RPRX) September 23, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-23
Royalty Pharma plc (RPRX) September 23, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
Royalty Pharma plc (RPRX) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript
Confident tone
Portfolio Receipt Growth & Guidance Raise
Chloramatug (TTR Amyloidosis) Acquisition
China Market Opportunity
Revenue
$674.14M
▲ 16.5% YoY Diluted EPS
$0.04
▼ 42.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Royalty Pharma plc (RPRX) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Royalty Pharma plc (RPRX) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-13
Royalty Pharma plc (RPRX) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Confident tone
R&D Co-Funding
Portfolio Receipts Growth
Clinical and Regulatory Updates
Revenue
$630.58M
▲ 11% YoY Diluted EPS
$0.67
▲ 21.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-03
Royalty Pharma plc (RPRX) March 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-11
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
Confident tone
Financial performance and growth
Transaction pipeline and synthetic royalties
Capital deployment and shareholder returns
Revenue
$621.99M*
▲ 4.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2025-12-03
Royalty Pharma plc (RPRX) December 3, 2025 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-05
Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript
Confident tone
LP(a) clinical program (olpacican/alpacoran)
Portfolio receipts and top-line growth
Returns on capital
Revenue
$609.29M
▲ 7.9% YoY Diluted EPS
$0.66
▼ 45.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript
Confident tone
Portfolio Receipts growth and guidance raise
Clinical and product news across portfolio
External manager acquisition / internalization
Revenue
$578.66M
▲ 7.7% YoY Diluted EPS
$0.07
▼ 69.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript
Confident tone
Financial Performance and Guidance
Litifilimab / Biogen Partnership
Capital Allocation and Share Repurchases
Revenue
$568.25M
▲ 0% YoY Diluted EPS
$0.55
▲ 5400% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-10
Royalty Pharma plc (RPRX) Q4 2024 Earnings Call Transcript
Confident tone
Portfolio Receipts and financial performance
Internalization of external manager
Capital deployment and share repurchases
Revenue
$593.64M*
▼ 0.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Royalty Pharma plc (RPRX) Q3 2024 Earnings Call Transcript
Confident tone
Syndax / Niktimvo Deal
Portfolio Receipts Growth
Portfolio Products and Approvals
Revenue
$564.69M
▲ 5.3% YoY Diluted EPS
$1.21
▲ 656.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript
Confident tone
Portfolio receipts growth and raised guidance
Voranigo acquisition and commercial launch
Repeat business and partnership relationships
Revenue
$537.27M
▼ 0.2% YoY Diluted EPS
$0.23
▼ 54% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Royalty Pharma plc (RPRX) Q1 2024 Earnings Call Transcript
Confident tone
Frexalimab acquisition
Development-stage pipeline
Financial results and guidance
Revenue
$567.98M
▼ 17% YoY Diluted EPS
$0.01
▼ 98.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Royalty Pharma plc (RPRX) Q4 2023 Earnings Call Transcript
Confident tone
Portfolio growth and acquisitions
Financial performance and 2024 guidance
Tysabri biosimilar exposure
Revenue
$596.07M*
▲ 5.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Royalty Pharma plc (RPRX) Q3 2023 Earnings Call Transcript
Revenue
$536.31M
▼ 6.5% YoY Diluted EPS
$0.16
▼ 50% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Royalty Pharma plc (RPRX) Q2 2023 Earnings Call Transcript
Revenue
$538.20M
▲ 0.4% YoY Diluted EPS
$0.50
▼ 28.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Royalty Pharma plc (RPRX) Q1 2023 Earnings Call Transcript
Revenue
$683.97M
▲ 21.7% YoY Diluted EPS
$0.76
▲ 533.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Royalty Pharma plc (RPRX) Q4 2022 Earnings Call Transcript
Revenue
$565.75M*
▼ 1.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Royalty Pharma plc (RPRX) Q3 2022 Earnings Call Transcript
Revenue
$573.46M
▼ 2.1% YoY Diluted EPS
$0.32
▲ 33.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Royalty Pharma plc (RPRX) Q2 2022 Earnings Call Transcript
Revenue
$535.96M
▼ 3.4% YoY Diluted EPS
$0.70
▼ 35.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Royalty Pharma plc (RPRX) Q1 2022 Earnings Call Transcript
Revenue
$562.05M
▼ 1.9% YoY Diluted EPS
$0.12
▼ 33.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Royalty Pharma plc (RPRX) Q4 2021 Earnings Call Transcript
Revenue
$575.70M*
▲ 0.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Royalty Pharma plc (RPRX) Q3 2021 Earnings Call Transcript
Revenue
$585.77M
▲ 8.8% YoY Diluted EPS
$0.24
▼ 69.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Royalty Pharma plc (RPRX) Q2 2021 Earnings Call Transcript
Revenue
$554.96M
▲ 8.6% YoY Diluted EPS
$1.08
▲ 1100% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Royalty Pharma plc (RPRX) Q1 2021 Earnings Call Transcript
Revenue
$573.03M
▲ 14.4% YoY Diluted EPS
$0.18
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Royalty Pharma plc (RPRX) Q4 2020 Earnings Call Transcript
Revenue
$572.14M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Royalty Pharma plc (RPRX) Q3 2020 Earnings Call Transcript
Revenue
$538.40M
▲ 16% YoY Diluted EPS
$0.79
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-19
Royalty Pharma plc (RPRX) Q2 2020 Earnings Call Transcript
Revenue
$510.93M
▲ 11.7% YoY Diluted EPS
$0.09
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–35 of 35 webcasts
Key facts
CIK
1802768
CUSIP
G7709Q104
13F (30d)
542 filings
514 filers
Visit website
Investor relations